Organic disulfides
Medchemexpress LLC NX-2127 | 2416131-46-7 | C39H45N9O5 | 500 MG
Zelebrudomide (NX-2127) is an orally active PROTAC degrader that targets Bruton's Tyrosine Kinase (Btk). It inhibits the proliferation of BTKC481S mutant TMD8 cells more effectively than Ibrutinib. In vivo, it demonstrates potent degradation of BTK in cynomolgus monkeys and leads to superior tumor growth inhibition in both WT TMD8 and C481S mutant xenograft models in mice.
- Inhibits proliferation of BTKC481S mutant TMD8 cells
- Catalyzes the degradation of Ikaros (IKZF1) and Aiolos (IKZF3)
- Stimulates T cell activation and increases IL-2 production
- Demonstrates potent degradation of BTK in cynomolgus monkeys
- Leads to superior tumor growth inhibition in xenograft models in mice
Medchemexpress LLC NX-2127 | 2416131-46-7 | C39H45N9O5 | 25 MG
NX-2127 is an orally active PROTAC degrader that targets Bruton's Tyrosine Kinase (BTK). It inhibits the proliferation of BTKC481S mutant TMD8 cells more effectively than Ibrutinib. NX-2127 catalyzes the degradation of Ikaros (IKZF1) and Aiolos (IKZF3) and stimulates T cell activation.
- Inhibits proliferation of BTK-C481S mutant TMD8 cells
- Catalyzes degradation of Ikaros (IKZF1) and Aiolos (IKZF3)
- Stimulates T cell activation and increases IL-2 production
- Potently degrades BTK in cynomolgus monkeys in vivo
- Leads to dose-proportional exposure in plasma
- Results in superior tumor growth inhibition in both WT TMD8 and C481S mutant xenograft models in mice
Medchemexpress LLC Zelebrudomide (NX-2127) | 2416131-46-7 | C39H45N9O5 | 50 MG
Zelebrudomide (NX-2127) is an orally active PROTAC degrader that targets Bruton's Tyrosine Kinase (Btk). It inhibits the proliferation of BTKC481S mutant TMD8 cells more effectively than Ibrutinib and appears as a light yellow to yellow solid. The compound has a molecular weight of 719.83.
- Targets Bruton's Tyrosine Kinase (Btk)
- Inhibits the proliferation of BTKC481S mutant TMD8 cells
- Catalyzes the degradation of Ikaros (IKZF1) and Aiolos (IKZF3)
- Stimulates T cell activation
- Increases IL-2 production in primary human T cells
- Demonstrates potent degradation of BTK in cynomolgus monkeys in vivo
- Leads to superior tumor growth inhibition in both WT TMD8 and C481S mutant xenograft models in mice